rs11591147 — PCSK9 R46L

PCSK9 R46L — Nature's Blueprint for PCSK9 Inhibitor Drugs

rs11591147 encodes the R46L (p.Arg46Leu) variant in PCSK9, a serine protease that regulates LDL cholesterol by promoting degradation of LDL receptors in the liver.

This loss-of-function mutation is associated with 15-47% reductions in coronary heart disease risk , making it one of the most significant cardioprotective genetic variants discovered. The variant provided the biological proof-of-concept for PCSK9 inhibitor drugs¹¹ PCSK9 inhibitor drugs
monoclonal antibody medications like evolocumab and alirocumab that mimic the effects of this variant.

The Mechanism

The R46L variant is a missense mutation in exon 1 of PCSK9 that replaces arginine with leucine at position 46 . This amino acid substitution in the prodomain²² prodomain
the N-terminal region cleaved during PCSK9 maturation reduces PCSK9 protein secretion efficiency and plasma PCSK9 concentration . The result: more LDL receptors remain on liver cell surfaces, pulling more cholesterol out of circulation.

The variant reduces protein secretion, phosphorylation, and binding affinity for the LDL receptor , creating a lifelong reduction in LDL cholesterol from birth onward.

The Evidence

The R46L variant was first identified in Cohen et al.'s landmark 2006 NEJM study³³ Cohen et al.'s landmark 2006 NEJM study
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease of the Atherosclerosis Risk in Communities (ARIC) cohort.

Among 9,524 white subjects, 3.2% carried R46L and had 15% lower LDL cholesterol and a 47% reduction in coronary heart disease over 15 years of follow-up. The effect was dose-dependent: heterozygotes averaged 116 mg/dL LDL while the eight homozygotes averaged 112 mg/dL .

A 2010 meta-analysis⁴⁴ A 2010 meta-analysis
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease of three Danish cohorts totaling 66,698 subjects confirmed the effect.

R46L carriers had a 12% (0.43 mmol/L) reduction in LDL-C and a 28% reduction in risk of ischemic heart disease . Remarkably, the observed 28% risk reduction far exceeded the 5% reduction predicted by the LDL lowering alone , suggesting that lifelong exposure to lower LDL — not just magnitude of reduction — drives the benefit.

The CARDIA longitudinal study⁵⁵ CARDIA longitudinal study
tracking the same individuals from age 18 to 50 demonstrated this lifelong effect.

R46L carriers had significantly lower LDL at age 18 (84.4 vs 100.9 mg/dL) and maintained this advantage through middle age .

This long-term LDL reduction was associated with reduced carotid intima-media thickness and lower coronary calcification in middle age .

Even in familial hypercholesterolemia (FH) — a genetic disorder causing severe high cholesterol — the R46L variant exerts a protective effect.

In a cohort of 582 FH patients, the 3% carrying R46L had 11% lower LDL cholesterol and significantly lower cardiovascular disease risk compared to non-carriers . The variant doesn't cure FH, but it substantially attenuates the phenotype.

Beyond cardiovascular protection,

R46L carriers are protected against nonalcoholic fatty liver disease (NAFLD), NASH, and liver fibrosis , with an odds ratio of 0.42 for NAFLD in a study of 1,874 at-risk individuals.

Carriers also have lower carotid intima-media thickness and, in males, reduced erectile dysfunction prevalence

— both markers of systemic vascular health.

Practical Implications

If you carry one or two copies of the R46L variant (GT or TT genotypes), you have a naturally lower LDL cholesterol baseline and substantially reduced lifetime cardiovascular risk. This is not a reason to ignore cardiovascular health, but it does mean your starting point is more favorable than average. Your LDL may appear "borderline" when it's actually protective for you.

The R46L variant does not eliminate the need for lifestyle interventions — diet, exercise, not smoking — but it provides a genetic cushion. If you develop high LDL despite carrying R46L, investigate secondary causes: hypothyroidism, familial hypercholesterolemia from other genes (LDLR, APOB), or metabolic syndrome. In the rare event you need statin therapy, you may respond more favorably and require lower doses than predicted.

If you don't carry R46L (GG genotype), the existence of PCSK9 inhibitor drugs means pharmaceutical options can mimic the protective effects of this variant. These drugs — evolocumab, alirocumab, inclisiran — lower LDL by 50-60% and reduce cardiovascular events in high-risk populations. The biology discovered through R46L carriers has translated directly into therapy.

Interactions

PCSK9 R46L interacts with other lipid metabolism genes but does not require compound implication entries because its effect is independent and additive. Carriers of R46L who also have:

• APOE ε4 alleles (rs429358, rs7412) — the cardiovascular risk from APOE4 is partially offset by R46L's LDL-lowering effect, but APOE4 still increases Alzheimer's risk independent of cholesterol.
• LDLR or APOB mutations (familial hypercholesterolemia) — as demonstrated in the FH cohort studies, R46L attenuates but does not eliminate the severe LDL elevation. These individuals still require aggressive lipid management but start from a lower baseline.
• Statin metabolism variants (SLCO1B1 rs4149056, CYP3A4/5 variants) — R46L does not change statin pharmacokinetics, but carriers may achieve target LDL levels with lower statin doses due to their baseline advantage.

Other PCSK9 variants include gain-of-function mutations (E670G, D374Y, S127R) that increase LDL and cardiovascular risk, and additional loss-of-function mutations (Y142X, C679X — predominantly in African populations) that confer even stronger protection than R46L. These are distinct variants, not alleles of the same SNP, so there is no compound heterozygosity with R46L at this locus.